Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Davide Rossi

Showing results (351-360 of 504) with videos related to

Pageof 51
Sort By:
Haematologica|February 24, 2018
Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasiasBernhard Gerber, Martina Manzoni, Valeria Spina, et al.
British Journal of Haematology|April 4, 2017
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-upPaola Ghione, Elisa Genuardi, Davide Rossi, et al.
Annals of Hematology|June 14, 2014
NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatmentMichele Dal Bo, Maria Ilaria Del Principe, Federico Pozzo, et al.
British Journal of Haematology|February 18, 2020
Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutationsSara Raponi, Caterina Ilari, Irene Della Starza, et al.
Cell Reports|January 7, 2014
Genetics of follicular lymphoma transformationLaura Pasqualucci, Hossein Khiabanian, Marco Fangazio, et al.
Haematologica|August 22, 2015
A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patientsAlessandra Tedeschi, Davide Rossi, Marina Motta, et al.
British Journal of Cancer|October 16, 2018
Mutant p53 blocks SESN1/AMPK/PGC-1α/UCP2 axis increasing mitochondrial O<sub>2-</sub>· production in cancer cellsMarco Cordani, Giovanna Butera, Ilaria Dando, et al.
Journal of Hematology & Oncology|November 29, 2013
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical applicationFederico Pozzo, Michele Dal Bo, Nadia Peragine, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 29, 2021
Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphomaMarco Fangazio, Erik Ladewig, Karen Gomez, et al.
British Journal of Haematology|August 16, 2023
ETS1 phosphorylation at threonine 38 is associated with the cell of origin of diffuse large B cell lymphoma and sustains the growth of tumour cellsElaine Y L Chung, Giulio Sartori, Maurilio Ponzoni, et al.
Pageof 51

Showing results (351-360 of 504) with videos related to

Sort By:
Pageof 51
Haematologica|February 24, 2018
Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasiasBernhard Gerber, Martina Manzoni, Valeria Spina, et al.
British Journal of Haematology|April 4, 2017
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-upPaola Ghione, Elisa Genuardi, Davide Rossi, et al.
Annals of Hematology|June 14, 2014
NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatmentMichele Dal Bo, Maria Ilaria Del Principe, Federico Pozzo, et al.
British Journal of Haematology|February 18, 2020
Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutationsSara Raponi, Caterina Ilari, Irene Della Starza, et al.
Cell Reports|January 7, 2014
Genetics of follicular lymphoma transformationLaura Pasqualucci, Hossein Khiabanian, Marco Fangazio, et al.
Haematologica|August 22, 2015
A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patientsAlessandra Tedeschi, Davide Rossi, Marina Motta, et al.
British Journal of Cancer|October 16, 2018
Mutant p53 blocks SESN1/AMPK/PGC-1α/UCP2 axis increasing mitochondrial O<sub>2-</sub>· production in cancer cellsMarco Cordani, Giovanna Butera, Ilaria Dando, et al.
Journal of Hematology & Oncology|November 29, 2013
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical applicationFederico Pozzo, Michele Dal Bo, Nadia Peragine, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 29, 2021
Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphomaMarco Fangazio, Erik Ladewig, Karen Gomez, et al.
British Journal of Haematology|August 16, 2023
ETS1 phosphorylation at threonine 38 is associated with the cell of origin of diffuse large B cell lymphoma and sustains the growth of tumour cellsElaine Y L Chung, Giulio Sartori, Maurilio Ponzoni, et al.
Pageof 51